Novel therapies highlighted at CLL ARC Forum

The first drug developed to specifically target a mutation involved in the pathogenesis of lymphoma, represents a ‘paradigm shift’ in the management of relapsed or refractory B-cell non-Hodgkin lymphomas. Speaking after the CLL ARC Forum in Sydney recently, Professor John Seymour told the limbic tazemetostat was ‘not going to be a household name’ but was important for ...

Already a member?

Login to keep reading.

© 2021 the limbic